More evidence of declining incidence of amyloidosis associated with inflammatory rheumatic diseases

Vasala, M.; Immonen, Kai; Kautiainen, Hannu; Hakala, M

doi:10.3109/03009741003747481

Cited by 13 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is however clear that rheumatoid arthritis related secondary amyloidosis is underdiagnosed or underreported because there are some 50,000 hospitalized rheumatoid arthritis patients in Sweden since 1964 [22]. Accordingly, amyloidosis incidence in rheumatoid arthritis patients in Finland has been 18 per million person-years when systematic amyloid determination was conducted [11]. The median survival time was 6 years in that study and it had been 3 years in an earlier Finnish study which probably shows that the control of the inflammation has a positive effect on survival [10,23].…”

Section: Discussionmentioning

confidence: 99%

“…In a re-evaluated Finnish autopsy series on rheumatoid arthritis deaths amyloid was found in 30% of cases and amyloidosis was considered the cause of death in 9.5% of rheumatoid arthritis patients [8,9]. According to causes of death in rheumatoid arthritis patients, 5.8% have been ascribed to amyloidosis but the proportion appears to be declining with time due to a better control of the inflammation [6,10,11]. Alzheimer disease is also a form of amyloidosis but because it is an independent diagnostic entity it will not be considered here.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and survival in non-hereditary amyloidosis in Sweden

Hemminki

Försti

et al. 2012

BMC Public Health

View full text Add to dashboard Cite

BackgroundAmyloidosis is a heterogeneous disease caused by deposition of amyloid fibrils in organs and thereby interfering with physiological functions. Hardly any incidence data are available and most survival data are limited to specialist clinics.MethodsAmyloidosis patients were identified from the Swedish Hospital Discharge and Outpatients Registers from years 2001 through 2008.ResultsThe incidence of non-hereditary amyloidosis in 949 patients was 8.29 per million person-years and the diagnostic age with the highest incidence was over 65 years. Secondary systemic amyloidosis showed an incidence of 1 per million and a female excess and the largest number of subsequent rheumatoid arthritis deaths; the median survival was 4 years. However, as rheumatoid arthritis deaths also occurred in other diagnostic subtypes, the incidence of secondary systemic amyloidosis was likely to be about 2.0 per million. The median survival of patients with organ-limited amyloidosis was 6 years. Most myeloma deaths occurred in patients diagnosed with unspecified or ‘other’ amyloidosis. These subtypes probably accounted for most of immunoglobulin light chain (AL) amyloidosis cases; the median survival time was 3 years.ConclusionsThe present diagnostic categorization cannot single out AL amyloidosis in the Swedish discharge data but, by extrapolation from myeloma cases, an incidence of 3.2 per million could be ascribed to AL amyloidosis. Similarly, based on rheumatoid arthritis death rates, an incidence of 2.0 could be ascribed to secondary systemic amyloidosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Incidence and survival in non-hereditary amyloidosis in Sweden

Hemminki

Försti

et al. 2012

BMC Public Health

View full text Add to dashboard Cite

show abstract

“…We observed a progressive decline in the incidence of amyloidosis during the study period, a finding that contrasts with the results of the Italian Registry , which shows an increase, mainly in the AA form. However, our results are consistent with recently published data demonstrating a decreased incidence of AA amyloidosis associated with rheumatic diseases and inflammatory processes . In our series, the decreasing trend especially affects the AA form, probably due to advances in the treatment of chronic infectious diseases (e.g.…”

Section: Discussionmentioning

confidence: 99%

Decreasing incidence of AA amyloidosis in Spain

Panizo

Rivera

López‐Gómez

2013

Eur J Clin Investigation

View full text Add to dashboard Cite

This is the largest series of renal amyloidosis in kidney biopsies published to date. We found amyloidosis to be decreasing slowly in Spain. This decrease affects both types and is confirmed in all cases marked in patients < 65 and in AA type. AA amyloidosis was the most frequent in our series. Patients affected by it were younger and had worse kidney function, with no differences in the level of proteinuria.

show abstract

“…Moreover, there was a significant reduction in AA amyloidosis patients with underlying juvenile idiopathic arthritis over this time period and a parallel increase in AA amyloidosis due to chronic infection related to intravenous and subcutaneous recreational drug use and AA amyloidosis of unknown aetiology. Several other small‐scale reports also indicated a decrease in AA amyloidosis secondary to rheumatological disease [89,90]. Patients with idiopathic AA amyloidosis have higher body mass index, are older and are more likely to be female compared to those with AA amyloidosis secondary to inflammatory conditions [91].…”

Section: Attr Amyloidosismentioning

confidence: 99%

Systemic amyloidosis from A (AA) to T (ATTR): a review

et al. 2020

View full text Add to dashboard Cite

Systemic amyloidosis is a rare protein misfolding and deposition disorder leading to progressive organ failure. There are over 15 types of systemic amyloidosis, each caused by a different precursor protein which promotes amyloid formation and tissue deposition. Amyloidosis can be acquired or hereditary and can affect various organs, including the heart, kidneys, liver, nerves, gastrointestinal tract, lungs, muscles, skin and soft tissues. Symptoms are usually insidious and nonspecific resulting in diagnostic delay. The field of amyloidosis has seen significant improvements over the past decade in diagnostic accuracy, prognosis prediction and management. The advent of mass spectrometry-based shotgun proteomics has revolutionized amyloid typing and has led to the discovery of new amyloid types. Accurate typing of the precursor protein is of paramount importance as the type dictates a specific management approach. In this article, we review each type of systemic amyloidosis to provide the practitioner with practical tools to improve diagnosis and management of these rare disorders.

show abstract

More evidence of declining incidence of amyloidosis associated with inflammatory rheumatic diseases

Abstract: Amyloidosis is rarely encountered today. ASFA or rectal biopsy facilitates its early diagnosis.

Cited by 13 publications

References 21 publications

Incidence and survival in non-hereditary amyloidosis in Sweden

Incidence and survival in non-hereditary amyloidosis in Sweden

Decreasing incidence of AA amyloidosis in Spain

Systemic amyloidosis from A (AA) to T (ATTR): a review

Contact Info

Product

Resources

About